MedTrace Logo

Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer

NCT04669951 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-06-03

No results posted yet for this study

Summary

The aim of this study is to investigate urokinase Plasminogen Activator Receptor (uPAR) microexpression in gastroesophageal cancer (adenocarcinomas) both qualitatively and semi-quantitatively and to evaluate if it offers a possibility for future imagining purposes.

Conditions

  • Esophagus Cancer, Adenocarcinoma

Interventions

OTHER

uPAR immunohistochemistry

Resected esophageal cancer will be qualitatively and semi-quantitatively analyzed for uPAR expression

Sponsors & Collaborators

  • Michael Patrick Achiam

    lead OTHER

Principal Investigators

  • Michael Achiam, MD., Ph.D · Rigshospitalet, Department of Surgical Gastroenterology

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-18
Primary Completion
2020-11-30
Completion
2020-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04669951 on ClinicalTrials.gov